

1
2 **Dietary Toll-like Receptor Stimulants Promote Hepatic**
3 **Inflammation and Impair Reverse Cholesterol Transport in Mice**
4 **via **Macrophage**-Dependent Interleukin-1 Production**

5
6
7 Tola A Faraj (PhD)^{1,2}, Cordula Stover (Dr med, PhD)³, Clett Erridge (PhD)^{1,4*}

8
9 ¹ Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Groby
10 Road, Leicester, UK

11 ² Department of Pharmacognosy, Hawler Medical University, Erbil, Kurdistan, Iraq

12 ³ Department of Infection, Immunity and Inflammation, Maurice Shock Medical Sciences
13 Building, University Road, Leicester, UK

14 ⁴ School of Life Sciences, Anglia Ruskin University, East Road, Cambridge, UK

15
16 *Address correspondence to:

17 Dr Clett Erridge

18 clett.erridge@anglia.ac.uk

19
20 Running title

21 Dietary PAMPs regulate RCT in mice

22
23 Figures: 11 (plus 3 in supplement)

24 Word count: 10,852

25
26

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

ABSTRACT

Background

The mechanisms connecting dietary intake of processed foods with systemic inflammatory markers and cardiovascular risk remain poorly defined. We sought to compare the abundance of pro-inflammatory stimulants of innate immune receptors in processed foods with those produced by the murine ileal and caecal microbiota, and to explore the impact of their ingestion on systemic inflammation and lipid metabolism *in vivo*.

Methods and results

Calibrated receptor-dependent reporter assays revealed that many processed foods, particularly those based on minced meats, contain pro-inflammatory stimulants of Toll-like receptor (TLR)-2 and TLR4 at concentrations which greatly exceed those produced by the endogenous murine ileal microbiota. Chronic dietary supplementation with these stimulants, at concentrations relevant to those measured in the Western diet, promoted hepatic inflammation and reduced several markers of reverse cholesterol transport (RCT) in mice. Hepatocytes were found to be insensitive to TLR2- and TLR4-stimulants directly, but their secretion of functional cholesterol acceptors was impaired by interleukin (IL)-1 β released by TLR-responsive **hepatic macrophages**. Hepatic macrophage priming by high-fat diet enhanced the impairment of RCT by ingested endotoxin, and this was reversed by macrophage depletion via clodronate liposome treatment, or genetic deficiency in the IL-1 receptor.

Conclusion

These findings reveal an unexpected mechanism connecting processed food consumption with cardiovascular risk factors, and introduce the food microbiota as a potential target for therapeutic regulation of lipid metabolism.

Keywords

Microbiota; inflammation; innate immunity; cholesterol metabolism; cardiovascular disease; diet

1
2 **INTRODUCTION**

3 Atherosclerosis is a chronic inflammatory disease of the arteries that represents the root
4 cause of the majority of cardiovascular diseases (1). Diet, inflammation and lipid metabolism
5 are well established risk factors for this disease. However, potential mechanisms linking these
6 factors remain to be clearly defined. In particular, the mechanisms by which adherence to the
7 Western dietary pattern increases circulating inflammatory markers and risk of coronary
8 artery disease (CAD), relative to prudent diets, remain poorly understood (2,3). Evidence
9 from murine models of diet-induced atherosclerosis suggests that inflammation triggered via
10 the innate immune receptors Toll-like receptor (TLR)-2 and TLR4 is likely to be involved
11 (4,5). However, the stimuli responsible for the triggering of atherogenic TLR-signalling, and
12 how these may relate to diet, lipid metabolism or CAD risk, remain to be established.
13

14 In earlier work, we found that many processed foods trigger inflammatory signalling in
15 human monocytes *in vitro* in a manner dependent on food content of the canonical ligands of
16 TLR2 and TLR4 (namely bacterial lipopeptides and lipopolysaccharides, LPS), which are
17 introduced into foods by common, non-pathogenic food spoilage bacteria (6,7). Human
18 feeding studies then showed that the consumption of diets rich in these TLR-stimulants
19 increased several markers of cardiovascular risk, including low-density lipoprotein (LDL)-
20 cholesterol and inflammatory markers, relative to a low TLR-stimulant run-in diet (8).
21 Likewise, nutritionally identical meals differing only in content of bacterial molecules had
22 opposing effects on the post-prandial induction of leukocyte inflammatory markers (8).
23

24 However, these findings were difficult to explain, since the human commensal microbiota
25 comprises ~100 trillion bacteria, and a burden of pro-inflammatory pathogen-associated
26 molecular patterns (PAMPs) that presumably far exceeds that contained in the diet (9,10).
27 Enterocytes are also reported to be largely unresponsive to apical TLR-stimulants, and when
28 their intracellular or basolateral TLRs are triggered, a barrier enhancing effect, rather than an
29 inflammatory response, is typically induced (11,12). Systemic absorption of appreciable
30 quantities of dietary PAMPs is also considered to be unlikely, as earlier studies demonstrated
31 extremely low or undetectable uptake of ingested endotoxin to serum, and no obvious
32 pathology in LPS feeding studies (13,14). In light of these observations, which are presumed
33 to reflect adaptations which limit host inflammatory responses to the commensal microbiota,
34 it is not clear how dietary TLR-stimulants, ingested at doses far lower than thought to be
35 present in the intestine, could alter systemic inflammatory tone or lipoprotein metabolism.
36

37 We therefore aimed to revisit these assumptions using a variety of approaches to PAMP
38 quantitation and tracking. Potential mechanisms connecting dietary PAMP intake with
39 systemic inflammatory signalling and lipid metabolism were then explored using genetic and
40 pharmacological approaches in murine models of dietary PAMP supplementation.
41

42 **METHODS**

43 **Mice**

44 Wild-type (WT) C57BL/6, and *Il1r1*^{-/-} mice fully backcrossed onto the C57BL/6 line,
45 were purchased from Charles River (UK) and used after 7 days acclimatisation at the
46 University of Leicester specific pathogen free (SPF) animal housing facility, or bred within
47 the facility for use in experiments from 7 weeks of age. Genotype was confirmed by PCR.
48 Male mice were used for all experiments **to limit the potential impact of oestrous cycle on**
49 **inflammatory markers**. Diets used were normal (low-fat) mouse chow (TestDiet, 5LF2), high
50

1 fat diet (TestDiet, 5TJN) and high cholesterol diet (TestDiet, 5TJT). Mice were randomly
2 allocated to control or PAMP treatment by technicians blinded to experimental outcomes, and
3 littermates were generally split to receive both treatments. All mouse experiments were
4 conducted according to Home Office guidelines and with institutional and Home Office
5 approval (PPL60/4332).

7 **Human subjects**

8 Peripheral blood mononuclear cells (PBMC) were prepared from venous blood collected
9 by venepuncture from healthy human volunteers with informed, written consent (age 22 - 35
10 years, n = 7, all male) according to the guidelines laid down in the Declaration of Helsinki
11 and with approval from the University of Leicester College of Medicine Research Ethics
12 Committee. Exclusion criteria included self-reporting of a previous diagnosis of any chronic
13 inflammatory disease (such as arthritis or inflammatory bowel disease), infection within the
14 previous 4 weeks or use of any medication other than oral contraceptives within the last
15 week.

17 **Preparation of food and microbiota extracts**

18 Foods from three major categories previously identified to be at high risk of containing
19 elevated levels of PAMPs (minced meat, diced onion and chocolate containing products (6))
20 were purchased from local supermarkets. Extracts were prepared by homogenising 25 g of
21 each product in 250 ml phosphate buffered saline (PBS). The samples were then clarified by
22 centrifugation (13,000 g for 5 min) and the resulting supernatant was filter-sterilised (0.22
23 µm, low-protein binding filters, Acrodisc). This step was taken to prevent the growth of
24 microbes during tissue culture, which would interfere with TLR-stimulant quantitation, and
25 also to represent the free, soluble PAMPs present in each sample, since these are more likely
26 to be absorbed from the gut lumen than PAMPs which remain attached to or within bacterial
27 cells. Samples were stored at -20°C before batch assay for TLR-stimulant content. Human
28 and murine stool samples were collected with informed consent and institutional ethical
29 approval and were processed in the same way.

31 **Quantification of TLR-stimulants**

32 We focussed specifically on quantitation of stimulants of TLR2 and TLR4 in this project
33 because inflammatory cytokine production by food extracts was found to be dependent
34 predominantly on signalling via these two receptors, and because both receptors play key
35 roles in murine atherogenesis (4,5). TLR-stimulants were quantified in aqueous extracts of
36 food, stool or ileal content samples using a HEK-293 TLR-transfection assay as described
37 previously (6). Briefly, HEK-293 cells cultured in 96 well plates were transfected with
38 plasmids coding for the following genes: human (h)TLR2, hTLR4 (co-expressing hMD-2) or
39 hTLR5 (each 30 ng, Invivogen), hCD14 (30 ng), thymidine-kinase promoter driven renilla
40 reporter (internal transfection efficiency control, 10 ng) and NF-κB-sensitive luciferase-
41 reporter (10 ng). Cells were grown for 3 days post transfection prior to 18 h challenge with
42 extracts diluted 1:10 in **Dulbecco's Modified Eagles Medium (DMEM) / 1% Foetal Calf**
43 **Serum (FCS)**. Standard curves were prepared in all sample measurement plates using serial
44 dilutions of Pam₃CSK₄, *E. coli* LPS or *S. typhimurium* flagellin. NF-κB reporter expression
45 was calculated as fold induction relative to cells cultured in medium alone, and compared
46 with the standard curve to yield the biological activities of each type of TLR-stimulant in the
47 samples, relative to the respective standard. As transfected cells were sensitive to a minimum
48 of 0.1 ng/ml LPS or Pam₃CSK₄, the minimum concentration of food-borne PAMPs detectable
49 by the assay was 10 ng LPS- or Pam₃CSK₄-equivalents per g food.

1 Dietary PAMP supplementation and oral gavage experiments

2 For chronic PAMP treatment, WT or *Il1r1*^{-/-} mice were given *ad libitum* normal chow and
3 drinking water which was unmodified (control group), or supplemented with 100 µg/ml *E.*
4 *coli* O111:B4 LPS, 1 µg/ml Pam₃CSK₄ and 1 µg/ml iEDAP (D-gamma-Glu-meso-
5 diaminopimelic acid, a component of peptidoglycan) (PAMP group), for 8 weeks (WT mice).
6 The chosen TLR-stimulant concentrations are comparable with the higher range of
7 concentrations measured in foods (up to 28 µg Pam₃CSK₄-equivalent TLR2-stimulants per
8 gramme of minced pork, and up to 10 µg *E. coli* LPS-equivalent TLR4-stimulants per
9 gramme of diced onion, Figure 1A-C), when accounting for the ~250-fold reduced
10 responsiveness of mice to endotoxin compared to man (15). In experiments involving acute
11 oral PAMP challenge, mice were orally gavaged with 200 µl of saline alone or containing 1
12 mg Pam₃CSK₄, 1 mg iEDAP or 2 mg *E. coli* LPS, as described in figure legends.

13 Cells and reagents

14 The PRR-stimulants Pam₃CSK₄, iEDAP and *Salmonella typhimurium* flagellin were from
15 Invivogen. *E. coli* O111:B4 LPS was from Sigma. Oxidised palmitoyl arachidonyl
16 phosphatidyl choline (OxPAPC) was prepared by air oxidation of native PAPC (Sigma) as
17 described previously (16). Briefly, 1 mg of PAPC in chloroform was evaporated to dryness
18 under nitrogen in a glass tube. The lipid film was then exposed to air in darkness for 72 h
19 before resuspension to 2 mg/ml in chloroform and storage under nitrogen at -80°C. Aliquots
20 of stock OxPAPC were dried under nitrogen in microtubes immediately before use and
21 vortexed into pre-warmed tissue culture medium for 30 s before addition to cells. Human
22 embryonic kidney (HEK)-293 cells (ECACC 85120602) and HepG2 cells (ECACC
23 85011430) were cultured in DMEM with 10% foetal calf serum (FCS) (Sigma). The murine
24 macrophage cell-lines RAW 264.7 (ECACC 91062702) and J774A.1 (ECACC 91051511)
25 were cultured in RPMI with 10% FCS. Testing of cell-lines for mycoplasma contamination
26 by PCR revealed no such infections, and cells were routinely cultured with Plasmocin
27 (Invivogen) to prevent growth of mycoplasma. Recombinant IL-1β, IL-6 and TNF-α were
28 from Peprotech EC Ltd. Neutralising anti-IL-1β antibody was from R&D Systems (AF-201-
29 NA, used at 2 µg/ml).

31 Human monocyte culture and challenge

32 Peripheral blood mononuclear cells (PBMC) were prepared by density gradient
33 centrifugation at 800 g for 25 min using Histopaque-1077 (Sigma). Recovered cells were
34 washed twice in PBS, resuspended in RPMI with 10% FCS and plated in 96-well plates at 4 x
35 10⁵ cells per well. Monocytes were prepared from PBMC by plastic adherence (1 h at 37°C),
36 followed by gentle washing to remove non-adherent cells. Remaining monocytes, which were
37 of ~85-90% purity as measured by CD14 staining by flow cytometry, were then challenged
38 by adding a 1:20 dilution of each filter-sterilised food extract in tissue culture medium. For
39 inhibition of TLR2 and TLR4, OxPAPC was used at 30 µg/ml, as this has been shown
40 previously to result in specific inhibition of TLR2 and TLR4 signalling, but not signalling
41 initiated via other TLRs or cytokine receptors.(17,18) Production of TNF-α was measured at
42 4 h, and IL-1β and IL-6 at 24 h, by ELISA (R&D).

44 Bacterial culture and 16S ribosomal (r)RNA gene qPCR

45 TLR-stimulant secretion was measured in conditioned media of the following members of
46 the food or human commensal microbiota: *Lactobacillus plantarum* (NCIMB-6376),
47 *Escherichia coli* (NCTC-13114), *Xanthomonas campestris* (8004), *Pseudomonas fluorescens*
48 (SBW25), *Pseudomonas fluorescens* (WCS365), *Pectobacterium atrosepticum* (ECG12) and
49 *Erwinia chrysanthemi* (EC16) were kindly provided by Dr Rob Jackson, University of
50

1 Reading. *Bacteroides fragilis* (NCTC-9343) and *Bifidobacterium bifidum* cells and
2 supernatant were kind gifts of Professor Ian Poxton (University of Edinburgh). *Streptococcus*
3 *pneumoniae*, *Staphylococcus aureus*, *Pseudomonas diminuta*, *Enterococcus faecalis*,
4 *Pseudomonas aeruginosa*, *Salmonella typhimurium* were University of Strathclyde teaching
5 laboratory reference strains kindly provided by David McNeill (University of Strathclyde).
6 Each strain was grown in respective standard broths and conditions to absorbance at 600 nm
7 of 1.0, and centrifuged to pellet bacterial cells (13,000 g for 5 minutes). The conditioned
8 medium was then filter-sterilised and stored at -20°C prior to assay. For 16S ribosomal RNA
9 (rRNA) gene qPCR, DNA was extracted from food and stool samples using the Qiamp Stool
10 DNA extraction kit (Qiagen). Total historical bacterial growth was measured by quantitative
11 PCR using the universal 16S rRNA gene primers 926F (AAACTCAAAGGAATTGACGG)
12 and 1062R (CTCACRRCACGAGCTGAC), as described previously (19). The
13 proteobacterial 16S rRNA gene specific primers 1080gF (TCGTCAGCTCGTGTGTGTA)
14 and g1202R (CGTAAGGGCCATGATG) were then used to measure the percentage of this
15 total which was derived from growth of proteobacteria. Samples were quantitated relative to
16 an internal standard (*E. coli* NCTC-13114 genomic DNA) using a Rotorgene thermal cycler
17 (Qiagen).

18

19 **Histology and immunohistochemistry**

20 For histology and some immunohistochemistry experiments, mouse tissue samples were
21 fixed in 4% paraformaldehyde overnight before processing to wax blocks. 5 µm sections
22 were then subjected to haematoxylin and eosin (H&E) staining according to standard
23 protocols. For hepatic F4/80, TLR2 and TLR4 immunofluorescence imaging, tissue samples
24 were frozen immediately in optimal cutting temperature compound (CellPath) and stored at -
25 80°C. 7 µm sections were then prepared using a cryostat (Leica CM3050S). Antibodies used
26 were rat-anti-mouse F4/80 (Abd Serotec, MCA497GA, 1:100) with AF488-goat-anti-rat
27 (Invitrogen, A-11006, 1:500) or rabbit anti-rat HRP Fab'2 (Abd Serotec, STAR21B, 1:100)
28 secondaries. Rabbit anti-mouse TLR2 (Santa-cruz, sc10739, 1:100) and rabbit anti-mouse
29 TLR4 (Santa-cruz, sc10741, 1:100) used AF594-labelled goat anti-rabbit secondary
30 (Invitrogen, A-11037, 1:500). Nuclei were stained using ProLong® Gold Antifade Reagent
31 containing DAPI (Invitrogen). Histological markers of intestinal inflammation were
32 considered to include mononuclear or polymorphonuclear cell infiltrates, or reduced mean
33 villus height.

34

35 **ELISA and Western blots**

36 **Serum amyloid A** (SAA) was measured in mouse plasma by ELISA (Abcam). Human and
37 mouse IL-1β, IL-6 and TNF-α levels were measured by respective DuoSet ELISA kits
38 (R&D). Western blots were probed with antibodies targeting IL-1β (Peprotech, 500-P51,
39 1:1,000), ApoAI (Cell Signalling Technology, 3350S for human, 1:250, Santa-cruz sc-30089
40 for mouse, 1:250) or glyceraldehyde 3-phosphate dehydrogenase (GAPDH, Santa-cruz, sc-
41 25778, 1:2,000). Serum ApoAI levels were measured by densitometry following Western blot
42 using ImageQuant software (GE Healthcare), and normalised to total plasma protein,
43 measured using the bicinchoninic acid assay (Pierce).

44

45 **Lipoprotein and cholesterol efflux assays**

46 For depletion of ApoB-containing lipoproteins from mouse serum samples, 10 µl of 20%
47 polyethylene glycol (PEG) in 200 mM glycine buffer, pH 7.4, was added to 25 µl serum,
48 incubated at room temperature for 20 minutes, then centrifuged at 10,000 g for 30 minutes to
49 pellet complexed ApoB lipoproteins. The remaining ApoB-depleted serum was used for
50 measurement of HDL-C (using the Amplex cholesterol assay, Invitrogen), and serum

1 cholesterol efflux capacity, which was measured as previously described (20). Briefly, J774
2 macrophages were plated at 3×10^5 cells per well of 24-well plates and labelled overnight with
3 $67 \text{ kBq/mL } ^3\text{H}$ -cholesterol (Perkin-Elmer). After equilibration for a further 6 h in DMEM
4 containing 14 mM HEPES, cells were cultured with 500 μl efflux medium (MEM containing
5 14 mM HEPES and 0.15 mM cAMP) supplemented (or not) with 14 μl ApoB-depleted
6 serum. After 4 h, effluxed and cell-bound cholesterol was measured by scintillation. For
7 measurement of functional cholesterol acceptors secreted by HepG2 cells, 50 μl of HepG2
8 cell conditioned medium was added to 450 μl of efflux medium in the J774 assay.
9 Triglycerides and glucose levels were measured in fasted mouse serum using kits from Wako
10 and Invitrogen, respectively.

11 **Measurement of LPS translocation**

12 LPS activity was measured in mouse plasma samples using the Pyrochrome limulus
13 amoebocyte lysate (LAL) assay (Associates of Cape Cod, UK) after recovery of LPS
14 bioactivity by heat treatment (70°C for 10 minutes). LAL-activities were determined by
15 kinetic analysis of each reaction using a temperature controlled microplate reader (BMG
16 Lumistar), as previously described (8). Serum LPS levels were below the limit of detection
17 using the HEK-293 TLR4 transfection assay. In some experiments, mice were orally gavaged
18 with 200 μl saline containing either 1 mg fluorescein isothiocyanate (FITC)-LPS (Sigma), or
19 15 mg FITC-dextran (MWT 4 kDa, Sigma) with 2 mg *E. coli* LPS. FITC-LPS translocation
20 to intestinal villi was monitored at 2.5 h by fluorescence microscopy. Percentage
21 translocation of FITC-dextran was quantified by fluorescence of plasma samples collected by
22 cardiac puncture 1.5 hours after oral gavage, in comparison with respective standard curves.
23 For quantitation of translocation of luminal LPS to tissues, mice were orally gavaged with 1
24 mg ^3H -labelled LPS in 200 μl PBS. For ^3H -labelling, *E. coli* cells were cultured to an optical
25 density of 0.9 at absorbance of 600 nm in broth supplemented with 0.74 MBq ^3H -acetate
26 (Perkin-Elmer) per ml as previously described (21). LPS was then extracted by the MgCl_2
27 precipitation method as previously described (22), yielding a specific activity of 3 kBq/mg.
28 Organs were extracted 4 h post-gavage, and 100 mg of each tissue was homogenised in 1 ml
29 0.1% sodium dodecyl sulfate (SDS) / 0.2M NaOH using a bead homogeniser (Precellys).
30 Radiolabel content of tissue extracts was quantified by scintillation.

31 **Priming experiments**

32 In experiments aiming to increase absorption of LPS from the gut lumen, mice were fed
33 HFD for 4 weeks, or orally gavaged with 2 (low dose) or 10 (high dose) mg/kg indomethacin,
34 24 h before oral gavage with 2 mg *E. coli* LPS or fluorescent markers as described above. In
35 experiments aiming to increase *in vivo* sensitivity to LPS, mice were fed HFD or high
36 cholesterol diet for 4 weeks before oral gavage with 2 mg *E. coli* LPS (23,24). Alternatively,
37 mice fed normal chow received intravenous injection of 200 μl normal saline containing 1 mg
38 heat-killed (60°C , 1 h) *Propionibacterium acnes*, 7 days before oral gavage with 2 mg *E. coli*
39 LPS.

40 **Clodronate liposome treatment**

41 22 male C57 mice were given unrestricted access to high fat diet (5TJN) and normal
42 drinking water for 4 weeks. All mice then received an intraperitoneal injection with 1 mg
43 clodronate liposomes (www.clodronateliposomes.com) in 200 μl saline. 72 h later, mice were
44 orally gavaged with 200 μl PBS alone or containing 2 mg *E. coli* LPS (n=11 per group).
45 Blood was collected by cardiac puncture 24 h after oral gavage. Liver sections were stained
46 for F4/80 positivity to monitor effects of clodronate liposome treatment on hepatic
47 macrophage number.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

Flow cytometry

For mouse primary **hepatic macrophage** and hepatocyte flow cytometry, 10^5 cells were labelled with 4 $\mu\text{g}/\text{ml}$ of isotype control antibody (rat IgG2a-PE, Cambridge Bioscience 400507, **1:50**), rat anti-mouse TLR2-PE (Cambridge Bioscience, 148603, **1:50**) or anti-TLR4-PE (Cambridge Bioscience, 145403, **1:50**). For human monocyte, PBMC and HepG2 cell-line flow cytometry, antibodies used were AF488-labelled anti-TLR2, anti-TLR4 and mouse IgG2a-K isotype control (eBioscience, 53-9922-41, **1:20**, 53-9917-41, **1:20** & 53-4724-80, **1:50**). Data were acquired using a Gallios cytometer (Beckman Coulter).

Hepatocyte and **hepatic macrophage** isolation

Mouse primary hepatocytes and **hepatic macrophages** were prepared by the three-step perfusion method as described previously, (25) with the following modifications. Livers were perfused by cannula via the vena cava and drained via the portal vein with the following buffers in sequence: (i) 25 ml clearing medium (**Hanks balanced salt solution** with 0.5 mM EGTA, pH 7.4), (ii) 10 ml PBS, (iii) 25 ml digestion buffer (DMEM with HEPES and 0.5 mg/ml type IV collagenase (Sigma)). A perfusion pump was used to regulate flow to ~ 4 ml/minute and a water bath jacket was used to maintain buffers at 37°C during perfusion. Once the liver had swollen indicating successful digestion of collagen, it was carefully excised, the gall bladder removed, and cells extracted by gentle agitation in isolation medium (ice cold DMEM with HEPES, penicillin, streptomycin and 10% foetal calf serum). Hepatocytes and **hepatic macrophages** were then isolated by the differential density method as described previously. (25) Briefly, mixed liver cell suspensions were centrifuged at 4°C for two minutes at 50 g. The hepatocyte-rich pellet was resuspended in 25 ml of cold isolation medium and the centrifugation procedure was repeated twice more (2 minute, 50 g washes) to further purify the hepatocytes. Hepatocytes were then plated at 100,000 viable cells per well of collagen coated 24-well plates, allowed to attach for 1 hour at 37°C , and then cultured in growth medium (DMEM with 10% FCS) overnight before use in experiments. Macrophages were collected from the supernatant of this first wash, purified by further centrifugations at 50 g, **then plated at 80,000 viable cells per well of non-coated 24-well plates**, allowed to adhere without collagen for 16 minutes at 37°C , then washed to remove residual hepatocytes, sinusoidal and endothelial cells. Cell purity was measured by flow cytometry for the TLR2 antigen, which was expressed by $>90\%$ of isolated macrophages, but undetectable on hepatocytes isolated as above. For mouse liver slice culture, livers were excised immediately after euthanasia and tissue cylinders were prepared using a sterilised 1 cm diameter metal punch. Circular sections of 300 μm thickness were then prepared in ice-cold RPMI medium using a Microslicer DTK-1000 vibratome. Sections were cultured in independent wells of 24-well plates and challenged with PAMPs or cytokines for 24 hours before measurement of cytokine production by ELISA. Because IL- 1β production was below the limit of detection in this system, liver slice culture was not pursued in further experiments.

Statistical Analyses

In experiments where more than two groups were compared, one way **analysis of variance (ANOVA)** was performed using Tukey's or Dunnett's post-test. In experiments where two groups were compared, unpaired, two-tailed Student's T-tests, or the Mann-Whitney U-test, were used. Food and intestinal PAMP concentrations were \log_{10} -transformed before analysis. Differences were assumed to be significant at $P < 0.05$. Each point plotted on categorical scatter plots corresponds to measurements taken from independent mice. Biological rather than technical replicates are shown throughout. Error bars shown on bar charts are **standard error of the mean (SEM)**. Data were analysed using GraphPad Prism version 7.0.

RESULTS

The PAMP content of some commonly consumed foods can greatly exceed that of the endogenous murine ileal microbiota

Because the commensal microbiota is not evenly distributed along the gastrointestinal tract (9), we first sought to compare the relative biological activities of soluble stimulants of TLR2, TLR4 & TLR5 in the ileal contents of healthy mice, with those of murine and human stool samples, using a calibrated HEK-293 TLR-transfection assay (26). As expected, these stimulants were much more abundant in stool samples than in ileal contents (Figures 1A-C). However, a screen of a selection of foods previously identified to be at high risk of PAMP-contamination (minced meats, diced onion and chocolates (6)), revealed that many of these contained TLR-stimulants at levels which were 2-3 orders of magnitude higher than normally present in the ileum. Filter-sterilised homogenates of these foods were also more potent inducers of pro-inflammatory cytokine production than murine ileal contents (Figures 1D-F), and these responses were blocked completely by OxPAPC, a specific inhibitor of TLR2 and TLR4 (Figure 2A) (17). Antibiotic treatment, or autoclaving, prior to storage of minced meats also prevented the accumulation of TLR2-stimulants in these foods, along with their capacity to induce inflammatory cytokine production, confirming that TLR-stimulants accumulate in these foods through the activity of food-borne bacteria (Figures 2B,C).

We next explored how such foods may contain similar TLR-stimulant content to the murine faecal microbiota, despite containing lower levels of total bacterial 16S ribosome gene DNA (rDNA) (Figure 2D). Because earlier work has identified proteobacteria as key inducers of inflammatory signalling in the human intestinal microbiota and during food spoilage (7,26-28), we quantified their historical activity in samples using viability-independent qPCR. Meat and chocolate samples contained a much higher proportion of proteobacterial 16S rDNA relative to total bacterial 16S rDNA (61.9% and 14.2%), compared to mouse or human faecal microbiota samples (2.3% and 2.4%, Figure 2E). Conditioned media of selected proteobacteria also contained far more abundant soluble TLR2 and/or TLR4 stimulants than those of representative non-proteobacterial food and commensal organisms, further supporting the notion that this group may play a key role in determining the pro-inflammatory potential of extracts (Figures 2F,G). Together, these findings indicate that soluble stimulants of TLR2 and TLR4 are normally present at very low concentrations in the healthy ileum, but can be much more abundant in some processed foods, most likely due mainly to the historical activity of proteobacteria.

Dietary PAMP intake promotes hepatic inflammation and impaired RCT

To explore the potential impact of chronic intake of dietary PAMPs on inflammatory and metabolic markers, C57Bl/6 mice were fed normal chow for 10 weeks with or without supplementation of drinking water with stimulants of TLR2, TLR4 and **nucleotide-binding oligomerization domain-containing protein-1** (since NOD1-stimulants were also detected in minced meats, Figure 2H). The chosen concentration of lipopeptide was comparable with that measured in high-PAMP foods (6,7), as was that of LPS when accounting for the ~250-fold reduced responsiveness of mice to endotoxin compared to man (15). Chronic dietary intake of these PAMPs had no effect on weight gain, hepatic steatosis or a variety of inflammatory and regulatory cytokines, key markers of T-cell subset abundance, villus height or Paneth cell degranulation in ileum, or histological evidence of inflammation in stomach, ileum or colon (**Figures S1A-F, S2A-K**). Likewise, although PAMP treatment increased macrophage markers in adipose tissue (*Cd68* mRNA and F4/80 protein), there was no significant increase

1 in expression of inflammatory cytokines (*Il-1 β* , *Il-6* or *Tnf- α*) in fat (Figure S2E,H).
2 However, a number of markers of inflammation and the acute phase response (APR) were
3 upregulated in livers of PAMP-fed mice compared to controls, consistent with a ~6-fold
4 increase in hepatic F4/80⁺ macrophages (Figures 3A,B). Although PAMP treatment did not
5 significantly alter homeostatic model assessment of insulin resistance (HOMA-IR) or serum
6 triglycerides (Figures S2D,3C), total cholesterol was lower in serum of treated mice, driven
7 by significant reductions in HDL-C (Figure 3D). PAMP treatment also reduced hepatic
8 expression of *ApoAI* mRNA and serum ApoAI protein (Figures 3B,E), and significantly
9 impaired the capacity of ApoB-depleted serum to accept cholesterol effluxed from
10 macrophages - all key markers of the RCT pathway (Figure 3F).

11 12 **A far greater proportion of ingested endotoxin is absorbed than is detected by the** 13 **limulus assay**

14 We next aimed to quantify the fraction of ingested LPS that may translocate to blood.
15 Orally gavaged FITC-labelled LPS was detectable within occasional villi post-gavage (Figure
16 4A), but fluorescence was undetectable in blood, liver or spleen. Measurements made using
17 the more sensitive limulus assay, which is traditionally used for this purpose (29), also
18 suggested that only a very small proportion of the dose is absorbed to blood (~0.00004%,
19 assuming a mouse blood volume of 2 ml and 1 mg LPS ingested, Figure 4B). However,
20 because the capacity of LPS to stimulate the limulus assay is rapidly diminished by blood
21 proteins *in vivo* (30), we sought to measure tissue uptake of orally delivered ³H-labelled LPS.
22 This approach revealed that although little or no radiolabel was detected in heart, muscle,
23 lung or blood post-gavage (suggesting rapid clearance of absorbed LPS), there was
24 significant accumulation (~0.4% of the dose) of ³H-LPS in liver (Figure 4C). This raised the
25 possibility that sufficient LPS may be absorbed from the diet to trigger the hepatic
26 inflammation observed in earlier experiments. However, we found that oral delivery of the
27 tested PAMPs, alone or in combination, did not reproducibly induce dyslipidaemia or hepatic
28 inflammatory markers within 24 h in unprimed mice (Figure S3A-G). Attempts to increase
29 LPS absorption using indomethacin, an established enhancer of gut permeability (31),
30 resulted in markedly elevated serum LPS levels post-LPS-gavage, but hepatic APR markers
31 were still not reproducibly elevated, suggesting that the unprimed mouse liver displays low
32 responsiveness to relatively high levels of circulating LPS in health (Figure 5A-H).

33 34 **Hepatic macrophages mediate the APR and cholesterol efflux responses to dietary** 35 **endotoxin**

36 Our efforts to develop an acute model of oral-PAMP-induced APR for mechanistic studies
37 therefore refocused on increasing the sensitivity of mice to circulating LPS. Three previously
38 reported methods were employed: intraperitoneal administration of heat-killed
39 *Propionibacterium acnes*, 4 weeks priming with high fat diet (HFD) and 4 weeks priming
40 with high cholesterol diet (HCD) (23,24,32). While all three treatments increased hepatic
41 macrophage number and expression of F4/80, TLR2 and TLR4 from a low baseline, and
42 rendered mice responsive to orally delivered LPS within 24 h, only HFD priming yielded a
43 suitably low background of APR markers for detection of hepatic inflammation in response
44 to orally-delivered LPS (Figure 6A-E).

45
46 In HFD-primed mice, hepatic TLR2 and TLR4 protein, APR markers and circulating SAA
47 were significantly increased, and hepatic *ApoAI* expression, serum ApoAI, HDL-C and
48 cholesterol efflux capacity were all significantly decreased, 24 h after oral LPS treatment
49 (Figure 7A-G). Limulus and FITC-dextran assays showed that this increase in responsiveness
50 was not due to effects of HFD on intestinal permeability (Figures 5A,B). However, depletion

1 of hepatic F4/80⁺ macrophages (by ~98%, Figure 8A,B) using clodronate liposomes
2 abolished all of the observed responses to oral LPS (Figures 7B-G,8C,D). Oral LPS-induced
3 APR was not likely secondary to cytokines released from macrophages in the gut, vasculature
4 or adipose tissue, since no induction of the key APR-inducing cytokines *Il-1 β* , *Il-6* or *Tnf- α*
5 was observed in these tissues (Figures S1D,S2H,6I-K). However, hepatic macrophages
6 isolated from both LFD- and HFD-fed mice produced all of these cytokines in response to
7 Pam₃CSK₄ or LPS stimulation *ex vivo* (Figure 8E). The responsiveness of isolated hepatic
8 macrophages to these stimuli was not increased by HFD-priming, consistent with similar
9 levels of expression of TLR2 and TLR4 (Figures 8E,F). Taken together, these results suggest
10 that hepatic macrophages are key mediators of the lipid responses to orally delivered LPS,
11 and that their increased abundance in the liver, rather than cellular responsiveness to TLR-
12 stimulants, may be a key mechanism of HFD-induced responsiveness to orally delivered LPS.

14 IL-1 is a key mediator of dietary PAMP-mediated downregulation of ApoAI

15 Since we saw no effect of acute or chronic PAMP treatment on intestinal expression of
16 ApoAI (Figure S1D), which accounts for up to 30% of circulating ApoAI protein in mice
17 (33), we next explored the effects of PAMPs and cytokines on cholesterol acceptors
18 expressed by hepatocytes. IL-1 β , but not IL-6, TNF- α or ligands of TLR2, TLR4 or NOD1
19 significantly reduced ApoAI mRNA expression in human HepG2 hepatocytes (Figure 9A,B).
20 HepG2 cells also secrete HDL particles similar to those found in plasma (34), and we found
21 that the capacity of their conditioned medium to accept cholesterol effluxed from
22 macrophages was significantly reduced by IL-1 β , but not by IL-6, TNF- α or TLR-stimulants
23 directly (Figures 9C,D). This was consistent with reduced expression of ApoAI protein by
24 IL-1 β treatment and lack of expression of TLR2 or TLR4 protein in these cells and mouse
25 primary hepatocytes (Figures 9E,F). IL-1 β neutralising antibody also reversed the inhibition
26 of HepG2 ApoAI expression by supernatant of LPS-stimulated human monocytes, suggesting
27 a role for IL-1 β in myeloid cell-induced hepatocyte APR (Figure 9G).

28
29 To further explore the potential role of IL-1 in dietary PAMP induced APR and lipid
30 responses, we examined responses in mice lacking the IL-1 receptor. Primary hepatocytes
31 isolated from WT mice responded to supernatant of LPS-challenged WT hepatic
32 macrophages by reducing ApoAI mRNA, but this response was not observed in hepatocytes
33 isolated from *Il1r1*^{-/-} mice (Figure 10A). Likewise, although a modest SAA protein response
34 to orally-delivered LPS was preserved in HFD-primed *Il1r1*^{-/-} mice *in vivo* (Figure 10B), oral
35 LPS did not significantly alter hepatic ApoAI mRNA, serum ApoAI protein, HDL-C or serum
36 cholesterol efflux capacity in *Il1r1*^{-/-} mice (Figures 10C-E). Interestingly, unlike bone-
37 marrow-derived macrophages (BMDM), isolated WT hepatic macrophages released IL-1 β
38 protein without requirement for secondary inflammasome stimulus, despite containing lower
39 levels of intracellular IL-1 β protein and mRNA (Figures 10G-I). Together, these results
40 suggest that human and mouse hepatocytes are not directly responsive to TLR2 or TLR4
41 stimulants, but may respond to orally delivered LPS via IL-1 β released by activated hepatic
42 macrophages.

44 DISCUSSION

45 Previous studies of the mechanisms connecting microbes, innate immune signalling and
46 cardiometabolic risk have focussed largely on the resident intestinal microbiota (35-38).
47 Here, we introduce the concept that the food microbiota may also play a significant role in
48 this relationship, through several findings which are unexpected in light of earlier work.

1 First, we show that although soluble stimulants of TLR2 and TLR4 are abundant in the
2 gut, they are sequestered mainly in the large intestine, and can be orders of magnitude more
3 abundant in some processed foods than in the healthy ileum. At first glance, this seems
4 counter-intuitive since the human intestinal microbiota comprises >100 trillion bacteria and at
5 least 1 gramme of commensal-derived LPS - both of which greatly exceed any quantity that
6 would likely be ingested with food (9). However, we found that the bioactivity of LPS in the
7 human faecal microbiota is far lower (~200-fold) than predicted by numbers of Gram-
8 negative bacteria alone (10). This low activity is likely explained by the fact that the vast
9 majority (>99%) of the Gram-negative bacteria of the human large intestine are members of
10 the Bacteroidetes group (9,10), which tends to express endotoxin comprising a
11 monophosphoryl, penta-acyl lipid-A that does not stimulate human TLR4/MD2 (39-41). By
12 contrast, proteobacterial species (such as *E. coli*) tend to express a canonical, hexa-acyl bis-
13 phosphorylated lipid A, which is a potent agonist of human TLR4/MD2. The proportionate
14 abundance of proteobacterial 16S rDNA in the tested foods thus helps to explain how these
15 foods can be more immunostimulatory than the mouse faecal microbiota, despite containing
16 much lower total 16S rDNA and bacterial density (up to 10¹⁰ vs up to 10¹¹ CFU/g,
17 respectively (9,42)).

18
19 Consistent with earlier reports (14,29), our attempts to measure the absorption of ingested
20 LPS using the limulus assay suggested that the fraction which translocates to blood is
21 extremely small (0.00004%, Figure 4B). However, because circulating LPS is cleared rapidly
22 from the circulation (30), or otherwise masked from detection by limulus enzymes through
23 binding to blood proteins and lipoproteins (43), we sought to confirm this finding using a
24 radiolabel approach. This method revealed that a far greater proportion of ingested LPS is
25 absorbed (~0.4% to liver), than previously estimated using the limulus assay, raising the
26 possibility that LPS absorbed from some dietary sources may exceed the threshold required
27 to trigger hepatic inflammatory signalling.

28
29 Our attempts to explore this possibility using an acute model of LPS ingestion were based
30 on the well-established observation of robust acute-phase and lipid responses to intravenously
31 delivered LPS in mice within 24 h (15,20). However, no such responses were observed when
32 LPS was administered orally to healthy mice. Instead, some form of priming stimulus was
33 found to be necessary to render mice responsive to ingested LPS. Among a number of
34 approaches used to increase responsiveness to LPS (23,24,32), HFD-priming was found to be
35 the most effective. This priming effect was not likely due to effects of HFD on gut barrier
36 permeability, since although this has been reported to be increased by some groups (44), we
37 and others (45,46), did not see this, perhaps due to differences in diet composition.

38
39 Instead, it is more likely that priming is related to hepatic macrophage density, which was
40 significantly increased by all of the successful priming regimens (HFD, HCD, *P. acnes*
41 injection and chronic dietary PAMP exposure itself). This view is supported by the
42 observation that systemic responses to ingested LPS were ablated in mice treated with
43 clodronate liposomes. Notably, although clodronate liposome treatment depletes
44 macrophages in diverse tissues systemically, it is likely that hepatic macrophages, rather than
45 macrophages in other tissues, are the predominant mediators of the response to dietary
46 PAMPs in this context. For example, while key APR-inducing cytokines were induced in
47 liver in response to oral LPS, they were not upregulated in other macrophage-rich tissues,
48 including intestinal, adipose and vascular tissues (Figures S1D,S2H,6I-K). Also, unlike bone-
49 marrow derived macrophages, isolated hepatic macrophages released IL-1 β in response to
50 LPS without requirement for priming or secondary stimulus (Figure 8E).

1
2 Nevertheless, it should be acknowledged that hepatic macrophages are a highly
3 heterogeneous population, and further work will be required to establish which functional
4 subset is primarily responsible for the observed effects. In particular, it will be helpful to
5 explore whether the response is driven mainly by resident yolk-sac derived Kupffer cells
6 (KCs), or macrophages more recently recruited from the bone marrow, both of which may
7 stain positively for F4/80 and therefore were not distinguished by the present study (47).
8 Evidence suggests that both proliferation of resident KCs and recruitment from blood may
9 drive the accumulation of macrophages during liver injury, and the relative balance of these
10 subsets may help determine hepatic responsiveness to PAMPs, since the latter are established
11 to elicit more inflammatory responses to PAMPs than resident KCs (47).

12
13 Although we did not see an increase in triglyceride content in the livers of PAMP-fed mice
14 (Figure S2J), our findings may offer some insight to risk factors for non-alcoholic fatty liver
15 disease (NAFLD), since hepatic macrophages are reported to drive the condition in mice
16 (48), and their density is associated with severity of NAFLD in man (49). Markers of low-
17 grade inflammation, particularly those related to TLR-signalling, are also upregulated in
18 livers of obese patients compared to healthy controls (50), and the condition is more common
19 in subjects consuming the Western diet (which is relatively high in PAMPs) compared to the
20 Mediterranean diet (which is based more on low PAMP foods) (51).

21
22 The induction of inflammatory cytokines and APR signalling in the liver by ingested
23 PAMPs could also be of potential relevance to cardiovascular risk. Experimentally induced
24 APR-signalling, restricted specifically to hepatocytes, has been shown to accelerate
25 atherosclerosis in *ApoE*^{-/-} mice (52). Several lines of evidence also suggest that serum efflux
26 capacity, and the RCT pathway more generally, may be key regulators of cardiovascular risk.
27 For example, serum RCT capacity is inversely associated with CAD risk in man (53), and
28 protective roles have been demonstrated for RCT and ApoAI, in murine models of
29 atherosclerosis (54-56). It will be interesting to explore in further studies whether dietary
30 PAMP intake modifies atherogenesis in mice, or serum RCT function in man.

31
32 Our results also suggest a key role for IL-1 signalling in the ApoAI and efflux responses to
33 ingested LPS. For example, IL-1 β -neutralising antibody blunted the suppression of
34 hepatocyte *ApoAI* expression by the conditioned media of stimulated macrophages (Figure
35 9G), and responses to ingested LPS were also blunted or absent in *Il1r1*^{-/-} mice (Figure 10A-
36 E). Together, these findings support a model in which hepatic macrophage-dependent sensing
37 of food-borne PAMPs triggers a mild APR programme in hepatocytes, driven largely via
38 release of IL-1 β , resulting in the downregulation of ApoAI synthesis, reduced HDL-C and
39 impaired RCT to serum (Figure 11).

40
41 These findings offer useful new insight into the emerging understanding that IL-1 plays a
42 key role in the development of both NAFLD (48) and cardiovascular disease (1). For
43 example, the recent CANTOS trial showed that IL-1 neutralisation with Canakinumab
44 significantly reduced both APR markers and cardiovascular event rate in patients with a
45 history of myocardial infarction (1). However, a key question raised by these studies is what
46 might be the source and nature of the triggers for the IL-1 production underpinning these
47 findings. The present study suggests that dietary PAMPs may be a plausible candidate for IL-
48 1 stimulation in this context, and that IL-1 mediated reduction in RCT mediators may be a
49 mechanism for the protective activity of Canakinumab.

1 It should be acknowledged that TLR2 and TLR4 stimulants are well established to trigger
2 systemic inflammation and dyslipidaemia when delivered at high doses intravenously
3 (15,20). However, it has been generally assumed to date that these stimulants should not
4 induce similar effects when ingested. This view is based on the assumption that foods should
5 contain a far lower PAMP content than the intestinal microbiota, the observation of no
6 obvious deleterious phenotype (inflammatory or otherwise) following acute oral
7 administration of LPS or the TLR2-stimulant Pam₃CSK₄ to unprimed animal models (12,13),
8 the well-recognised abundance of TLR2- and TLR4-stimulants produced by the commensal
9 microbiota of the large intestine (10) and the presumed low absorbance of ingested PAMPs
10 (14,29). The present study provides evidence to counter each of these assumptions for the
11 reasons outlined above.

12
13 If present in man, this pathway also has potential to shed light on several key questions in
14 dietary epidemiology. For example, it remains unclear why the consumption of processed
15 meats increases risk of CAD and type II diabetes to a greater degree than their unprocessed
16 equivalents, which are otherwise identical in macronutrient content (57-59). Likewise, the
17 mechanisms connecting processed food consumption with systemic inflammatory markers in
18 cross-sectional studies are poorly defined (2,60,61). The present findings suggest that many
19 processed foods, particularly those based on minced meats, may contain a higher PAMP
20 content than their fresh or unchopped equivalents, due to historical overgrowth of
21 proteobacteria (7). The chronic consumption of such foods could therefore impact on markers
22 of systemic inflammation and lipid metabolism, via the mechanisms outlined above, as
23 supported by the results of our earlier dietary trials in human volunteers (8). Notably, our
24 findings do not suggest that commonly used probiotic or fermentative organisms should
25 induce similar effects, since almost all such bacteria are Gram-positive, and as such do not
26 produce LPS or shed abundant stimulants of other TLRs into their environment (Figure 2F
27 and ref 26).

28
29 In summary, we show that although the large intestine harbours a large microbial flora,
30 molecules released by the proteobacteria-dominated microbiota of some processed foods may
31 have potential to dysregulate inflammatory and metabolic pathways systemically when
32 ingested. This mechanism helps to explain the long-standing connection between processed
33 meat intake and metabolic disease, and introduces the food spoilage microbiota as an
34 unexpected potential mediator of cardiovascular risk. Further studies are warranted to test
35 whether cholesterol metabolism may be modified through simple interventions targeting the
36 food microbiota, or their pro-inflammatory products.

37 38 **AUTHOR CONTRIBUTIONS**

39 CE and TF performed experiments and analysed results. CE and CS secured funding for
40 and managed the project. CE planned the study and wrote the paper.

41 42 **NON-STANDARD ABBREVIATIONS AND ACRONYMS**

43 ApoAI - Apolipoprotein AI

44 APR - Acute phase response

45 CAD - Coronary artery disease

46 iEDAP - D-gamma-Glu-meso-diaminopimelic acid

47 GAPDH - Glyceraldehyde 3-phosphate dehydrogenase

48 HBSS - Hank's balanced salt solution

49 HOMA-IR - Homeostatic model assessment of insulin resistance

50 KC - Kupffer cell

- 1 LAL - Limulus amoebocyte lysate
2 LPS - Lipopolysaccharide
3 NAFLD - Non-alcoholic fatty liver disease
4 NOD - Nucleotide-binding oligomerization domain-containing protein
5 OxPAPC - Oxidised palmitoyl arachidonyl phosphatidyl choline
6 PAMP - Pathogen-associated molecular pattern
7 PBMC - Peripheral blood mononuclear cells
8 RCT - Reverse cholesterol transport
9 rDNA - Bacterial 16S ribosome gene DNA
10 SAA - Serum amyloid A
11 SPF - Specific pathogen free
12 TLR - Toll-like receptor
13 TNF - Tumour necrosis factor

14 15 **ACKNOWLEDGEMENTS**

16 We thank Prof Shu Ye (University of Leicester) for helpful discussions and advice, and
17 Professor Ian Poxton (University of Edinburgh), Dr Rob Jackson (University of Reading) and
18 Mr David McNeill (University of Strathclyde), for provision of bacterial strains and
19 conditioned media.

20 21 **SOURCES OF FUNDING**

22 This work was supported by a Wellcome Trust Institutional Strategic Support Fund award,
23 and a University of Leicester College of Life Sciences Research fellowship, awarded to CE.
24 TF was supported by a studentship funded by the Iraq Higher Committee for Education
25 Development (D-11-242).

26 27 **DISCLOSURES**

28 The authors declare no competing interests.

29 30 **REFERENCES**

- 31
1. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Anti-inflammatory Therapy with Canakinumab for Atherosclerotic Disease. *N Engl J Med* (2017) 377:1119-31.
 2. Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Stefanadis C. Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA Study. *J Am Coll Cardiol* (2004) 44:152-8.
 3. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med* (2013) 368:1279-90.
 4. Michelson KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. *Proc Natl Acad Sci USA* (2004) 101:10679-84.
 5. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. *J Clin Invest* (2005) 115:3149-56.
 6. Erridge C. The capacity of foodstuffs to induce innate immune activation of human monocytes in vitro is dependent on food content of stimulants of Toll-like receptors 2 and 4. *Br J Nutr* (2010) 20:1-9.
 7. Erridge C. Accumulation of stimulants of Toll-like receptor (TLR)-2 and TLR4 in

- meat products stored at 5 degrees C. *J Food Sci* (2011) 2:H72-H79.
8. Herieka M, Faraj TA, Erridge C. Reduced dietary intake of pro-inflammatory Toll-like receptor stimulants favourably modifies markers of cardiometabolic risk in healthy men. *Nutr Metab Cardiovasc Dis* (2016) 26:194-200.
 9. Berg RD. The indigenous gastrointestinal microflora. *Trends Microbiol* (1996) 4:430-5.
 10. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity of the human intestinal microbial flora. *Science* (2005) 308:1635-38.
 11. Abreu MT, Vora P, Faure E, Thomas LS, Arnold ET, Arditi M. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. *J Immunol* (2001) 167:1609-16.
 12. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. *Gastroenterology* (2007) 132:1359-74.
 13. Harper MS, Carpenter C, Klocke DJ, Carlson G, Davis T, Delaney B. *E. coli* lipopolysaccharide: acute oral toxicity study in mice. *Food Chem Toxicol* (2011) 49:1770-2.
 14. Tamai H, Kato S, Horie Y, Ohki E, Yokoyama H, Ishii H. Effect of acute ethanol administration on the intestinal absorption of endotoxin in rats. *Alcohol Clin Exp Res* (2000) 24:390-4.
 15. Copeland S, Warren HS, Lowry SF, Calvano SE, Remick D, Inflammation and the Host Response to Injury Investigators. Acute inflammatory response to endotoxin in mice and humans. *Clin Diagn Lab Immunol* (2005) 12:60-7.
 16. Watson AD, Leitinger N, Navab M, Faull KF, Horkko S, Witztum JL, et al. Structural identification by mass spectrometry of oxidised phospholipids in minimally oxidised low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. *J Biol Chem* (1997) 272:13597-607.
 17. Erridge C, Kennedy S, Spickett CM, Webb DJ. Oxidised phospholipid inhibition of toll-like receptor (TLR) signalling is restricted to TLR2 and TLR4 - roles for CD14, LPS-binding protein and MD2 as targets for specificity of inhibition. *J Biol Chem* (2008) 283:24748-59.
 18. Walton KA, Cole AL, Yeh M, Subbanagounder G, Krutzik SR, Modlin RL, et al. Specific phospholipid oxidation products inhibit ligand activation of Toll-like receptors 4 and 2. *Arterioscler Thromb Vasc Biol*. 2003;23:1197-1203.
 19. Bacchetti De Gregoris T, Aldred N, Clare AS, Burgess JG. Improvement of phylum- and class-specific primers for real-time PCR quantification of bacterial taxa. *J Microbiol Methods* (2011) 86:351-6.
 20. McGillicuddy FC, de la Llera Moya M, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, et al. Inflammation impairs reverse cholesterol transport in vivo. *Circulation* (2009) 119:1135-45.
 21. Warren HS, Glennon ML, Wainwright N, Amato SF, Black KM, Kirsch SJ, et al. Binding and neutralization of endotoxin by Limulus antilipopolysaccharide factor. *Infect Immun* (1992) 60:2506-13.
 22. Uchida K, Mizushima S. A simple method for the isolation of lipopolysaccharides from *Pseudomonas aeruginosa* and some other bacterial strains. *Agric Biol Chem* (1987) 51:3107-14.
 23. Huang H, Liu T, Rose JL, Stevens RL, Hoyt DG. Sensitivity of mice to lipopolysaccharide is increased by a high saturated fat and cholesterol diet. *J*

- Inflamm* (2007) 4:22.
24. Imajo K, Fujita K, Yoneda M, Nozaki Y, Ogawa Y, Shinohara Y, et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. *Cell Metab* (2012) 16:44-54.
 25. Severgnini M, Sherman J, Sehgal A, Jayaprakash NK, Aubin J, Wang G, et al. A rapid two-step method for isolation of functional primary mouse hepatocytes: cell characterization and asialoglycoprotein receptor based assay development. *Cytotechnology* (2012) 64:187-95.
 26. Erridge C, Duncan SH, Bereswill S, Heimesaat MM. The induction of colitis and ileitis in mice is associated with marked increases in intestinal concentrations of stimulants of TLRs 2, 4, and 5. *PLoS One* (2010) 5:e9125.
 27. Carvalho FA, Koren O, Goodrich JK, Johansson ME, Nalbantoglu I, Aitken JD, et al. Transient inability to manage proteobacteria promotes chronic gut inflammation in TLR5-deficient mice. *Cell Host Microbe* (2012) 12:139-52.
 28. Zhu W, Winter MG, Byndloss MX, Spiga L, Duerkop BA, Hughes ER, et al. Precision editing of the gut microbiota ameliorates colitis. *Nature* (2018) 553:208-11.
 29. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes* (2007) 56:1761-72.
 30. van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. *Blood* (1990) 76:2520-26.
 31. Sydora BC, Macfarlane SM, Walker JW, Dmytrash AL, Churchill TA, Doyle J, et al. Epithelial barrier disruption allows nondisease-causing bacteria to initiate and sustain IBD in the IL-10 gene-deficient mouse. *Inflamm Bowel Dis* (2007) 13:947-54.
 32. Romics L Jr, Dolganiuc A, Kodys K, Drechsler Y, Oak S, Velayudham A, et al. Selective priming to Toll-like receptor 4 (TLR4), not TLR2, ligands by *P. acnes* involves up-regulation of MD-2 in mice. *Hepatology* (2004) 40:555-64.
 33. Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, et al. Intestinal ABCA1 directly contributes to HDL biogenesis *in vivo*. *J Clin Invest* (2006) 116:1052-62.
 34. Thrift RN, Forte TM, Cahoon BE, Shore VG. Characterization of lipoproteins produced by the human liver cell line, Hep G2, under defined conditions. *J Lipid Res* (1986) 27:236-50.
 35. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature* (2011) 472:57-63.
 36. Fu J, Bonder MJ, Crenin MC, Tigchelaar EF, Maatman A, Dekens JA, et al. The gut microbiome contributes to a substantial proportion of the variation in blood lipids. *Circ Res* (2015) 117:817-24.
 37. Brandsma E, Kloosterhuis NJ, Koster MH, Dekker D, Gijbels M, van der Velden S, et al. A pro-inflammatory gut microbiota increases systemic inflammation and accelerates atherosclerosis. *Circ Res* (2019) 124:94-100.
 38. Skye SM, Zhu W, Romano KA, Guo C-J, Wang Z, Jia X, et al. Microbial transplantation with human gut commensals containing CutC is sufficient to transmit enhanced platelet reactivity and thrombosis potential. *Circ Res* (2018) 123:1164-76.
 39. Alhawi M, Stewart J, Erridge C, Patrick S, Poxton IR. *Bacteroides fragilis* signals

- through Toll-like receptor (TLR) 2 and not through TLR4. *J Med Microbiol* (2009) 58:1015-22.
40. d'Hennezel E, Abubucker S, Murphy LO, Cullen TW. Total Lipopolysaccharide from the Human Gut Microbiome Silences Toll-Like Receptor Signaling. *mSystems* (2017) 2:e00046-17.
 41. Vatanen T, Kostic AD, d'Hennezel E, Siljander H, Franzosa EA, Yassour M, et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. *Cell* (2016) 165:842-53.
 42. Jay JM, Vilai JP, Hughes ME. Profile and activity of the bacterial biota of ground beef held from freshness to spoilage at 5-7 degrees C. *Int J Food Microbiol* (2003) 81:105-11.
 43. Emancipator K, Csako G, Elin RJ. In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. *Infect Immun* (1992) 60:596-601.
 44. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. *Diabetes* (2008) 57:1470-81.
 45. Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermúdez-Humarán LG, et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. *EMBO Mol Med* (2011) 3:559-72.
 46. Kless C, Müller VM, Schüppel VL, Lichtenegger M, Rychlik M, Daniel H, et al. Diet-induced obesity causes metabolic impairment independent of alterations in gut barrier integrity. *Mol Nutr Food Res* (2015) 59:968-78.
 47. Weston CJ, Zimmermann HW, Adams DH. The role of myeloid-derived cells in the progression of liver disease. *Front Immunol* (2019) 10:893.
 48. Mirea AM, Tack CJ, Chavakis T, Joosten LAB, Toonen EJM. IL-1 family cytokine pathways underlying NAFLD: Towards new treatment strategies. *Trends Mol Med* (2018) 24:458-71.
 49. Park JW, Jeong G, Kim SJ, Kim MK, Park SM. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. *J Gastroenterol Hepatol* (2007) 22:491-7.
 50. Bertola A, Bonnafous S, Anty R, Patouraux S, Saint-Paul MC, Iannelli A, et al. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. *PLoS One* (2010) 5:e13577.
 51. Zelber-Sagi S, Salomone F, Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms. *Liver Int* (2017) 37:936-49.
 52. Luchtefeld M, Schunkert H, Stoll M, Selle T, Lorier R, Grote K, et al. Signal transducer of inflammation gp130 modulates atherosclerosis in mice and man. *J Exp Med* (2007) 204:1935-44.
 53. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. *N Engl J Med* (2011) 364:127-35.
 54. Hughes SD, Verstuyft J, Rubin EM. HDL deficiency in genetically engineered mice requires elevated LDL to accelerate atherogenesis. *Arterioscler Thromb Vasc Biol* (1997) 17:1725-9.
 55. Pászty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. *J Clin Invest* (1994)

- 94:899-903.
56. Moore RE, Navab M, Millar JS, Zimetti F, Hama S, Rothblat GH, et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. *Circ Res* (2005) 97:763-71.
 57. Fretts AM, Howard BV, McKnight B, Duncan GE, Beresford SA, Mete M, et al. Associations of processed meat and unprocessed red meat intake with incident diabetes: the Strong Heart Family Study. *Am J Clin Nutr*. (2012) 95:752-8.
 58. Micha R, Wallace SK, Mozaffarian D. Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus. A systematic review and meta-analysis. *Circulation* (2010) 121:2271-83.
 59. Rohrmann S, Overvad K, Bueno-de-Mesquita HB, Jakobsen MU, Egeberg R, Tjønneland A, et al. Meat consumption and mortality - results from the European Prospective Investigation into Cancer and Nutrition. *BMC Medicine* (2013) 11:63.
 60. Lopez-Garcia E, Schulze MB, Fung TT, Meigs JB, Rifai N, Manson JE, et al. Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. *Am J Clin Nutr* (2004) 80:1029-35.
 61. Fung TT, Rimm EB, Spiegelman D, Rifai N, Tofler GH, Willett WC, et al. Association between dietary patterns and plasma biomarkers of obesity and cardiovascular disease risk. *Am J Clin Nutr* (2001) 73:61-7.

1
2

FIGURE LEGENDS

Figure 1: The TLR-stimulant content of some processed foods can greatly exceed that of the normal mouse ileal microbiota

(A-C) Soluble TLR2, TLR4 and TLR5-stimulants were quantified in processed foods (n=14), mouse chow (n=6), mouse ileal ingesta (n=5), mouse faeces (n=10) and human faeces (n=6) using HEK-293-TLR transfectants. (D-F) Pro-inflammatory cytokine production by primary human monocytes (n=3 donors) exposed to extracts of mouse ileal ingesta, minced meat or chocolate (n=5 extracts of each type), diluted 1:10 (wt/vol) in culture medium. P-values vs ileal contents, ANOVA with Tukey's test.

Figure 2: The accumulation of TLR-stimulants in processed meat is dependent on the food microbiota

(A) Human primary monocytes were treated with filter-sterilised extracts of minced meat or diced onion, 1 ng/ml *E. coli* LPS or 100 ng/ml Pam₃CSK₄, with or without oxidised palmitoyl arachidonyl phosphatidyl choline (OxPAPC, an inhibitor of TLR2 and TLR4, n=4 volunteers). (B) NF-κB activation in HEK-293-TLR2 transfectants challenged with filter-sterilised extracts of minced meat samples when fresh, or at the 'best before date' (d7), with or without treatment with the antibiotics penicillin and streptomycin (P/S), or polymyxin-B (PMB, which specifically targets Gram-negative bacteria), or autoclaving before storage. (C) Cytokine responses of human primary monocytes to the same meat extracts (n=4 per group). (D) Total 16S rDNA in stool and food samples measured by qPCR (a culture-independent measure of historical bacterial activity). (E) Proportion of proteobacterial 16S rDNA in human and mouse faecal samples and meat and chocolate samples (n=5-7). (F) Relative biological activities of soluble TLR2- and TLR4-stimulants in filter-sterilised conditioned media of representative proteobacterial and non-proteobacterial organisms of the food and commensal microbiota (grown to A600=1.0), measured using HEK-293-TLR transfectants calibrated with Pam₃CSK₄ and *E. coli* LPS, respectively. (G) Inflammatory cytokine production by primary human monocytes cultured with 1:1,000 dilutions of the same conditioned media. (H) NF-κB reporter responses in HEK-293 cells transfected with NOD-1 and filter sterilised homogenates of minced meats. Error bars shown are SEM. P-values vs control condition (medium alone), ANOVA with Dunnett's test.

Figure 3: Chronic dietary PAMP intake induces hepatic inflammation and impairs serum cholesterol efflux capacity

WT mice (n=8/gp) were given normal chow and drinking water supplemented (PAMP) or not (Ctrl), with *E. coli* LPS, Pam₃CSK₄ and D-gamma-Glu-meso-diaminopimelic acid (iEDAP, a component of peptidoglycan which stimulates NOD1), for 8 weeks. (A,B) Hepatic F4/80⁺ cells per field and acute phase response (APR) mRNA. (C-F) Serum homeostatic model assessment of insulin resistance (HOMA-IR) and RCT mediators. P-values vs control condition, Student's T-test or ANOVA with Dunnett's test.

Figure 4: The absorption of ingested LPS is greatly underestimated by limulus and fluorescent assays for LPS uptake

(A) Immunofluorescence of ileal villi 90 minutes after gavage with saline (Ctrl) or FITC-LPS (arrow, green). (B) Serum LPS 2.5 h after oral gavage with saline alone, Pam₃CSK₄ or *E. coli* LPS, as measured using the LAL assay (n=4/gp). (C) Radiolabel in mouse tissues 4 h after oral gavage with 1 mg ³H-labelled LPS (n=4/gp), measured in CPM (counts per minute). P-values vs Ctrl (or blood levels of radiolabel for panel C), ANOVA with Dunnett's test.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

Figure 5: Increased gut barrier permeability is insufficient to reproducibly increase hepatic APR markers in response to a single oral gavage with LPS
Two different approaches were taken with to increase gut permeability and enhance translocation of LPS from gut lumen to serum: oral pre-treatment with 10 mg/kg indomethacin,(31) and 4 weeks high fat diet (HFD).(44) WT mice (n=4/gp) were then orally gavaged with 15 mg FITC-dextran and 2 mg *E. coli* LPS in 200 µl saline. Indomethacin, but not HFD, increased gut permeability to LPS and FITC-dextran, although with excessive background systemic inflammation (A-F). Lower dose indomethacin (2 mg/kg, n=12/gp), resulted in a ~14-fold increase in circulating LPS 90 minutes post LPS-gavage, and enabled a plasma serum amyloid A (SAA) response to LPS orally delivered later (G), but hepatic acute phase response (APR) mRNA markers were not reproducibly increased (H). Error bars shown are SEM. P-values vs control condition, ANOVA with Dunnett's test.

Figure 6: Development of an acute murine model of oral-LPS induced APR and dyslipidaemia
Three methods previously reported to increase the sensitivity of mice to circulating LPS were tested, (i) intraperitoneal administration of heat-killed *Propionibacterium acnes* (n=6 per group), (ii) 4 weeks priming with high fat diet (HFD, n=10 per group) or (iii) 4 weeks priming with high cholesterol diet (HCD), (n=12 per group).(23,24,32) (A) Hepatic F4/80⁺ (green) cell number was significantly elevated by all three treatments relative to control mice fed normal chow. (B) HCD and *P. acnes* treatment increased hepatic TLR2 and TLR4 protein expression (red) from a very low baseline. (C) Hepatic CD68, CD14, TLR2 and TLR4 mRNA responses to each treatment. (D) Representative overlay showing co-localisation of TLR2 (red) and F4/80 (green) staining, suggesting predominant expression of TLR2 on hepatic macrophages. Similar results were observed for TLR4. (E) Circulating serum amyloid A (SAA) protein was significantly elevated by orally delivered LPS at 24 h only in HFD-primed mice - baseline SAA (a measure of the acute phase response) was excessively raised in HCD and *P. acnes* primed mice. (F,G) Hepatic APR markers and apolipoprotein (Apo)-AI were not significantly increased by orally delivered LPS in HCD and *P. acnes* primed mice, respectively. (H) Mice fed HFD gained significantly more body weight than mice fed normal chow. (I) 4 weeks HFD did not significantly increase CD68 mRNA in abdominal adipose tissue. Orally delivered LPS did not induce inflammatory markers in abdominal adipose tissue (J), or aorta (K) of HFD-primed mice within 24 h. Error bars shown are SEM. P-values vs control condition, ANOVA with Dunnett's test.

Figure 7: Hepatic macrophages are key mediators of the lipid and acute phase responses to ingested LPS
WT mice (n=8-11/gp) were fed low-fat diet (LFD) or high-fat diet (HFD) for 4 weeks, with or without treatment with clodronate liposomes to deplete tissue macrophages. (A) F4/80 (green), TLR2 and TLR4 (red) immunofluorescence in livers of mice fed LFD or HFD for 4 weeks. (B) Hepatic acute phase response mRNA markers in saline (Ctrl) or LPS gavaged HFD-primed mice pretreated (or not) with clodronate liposomes (CL), n=8-11/gp. (C-G) Serum amyloid A (SAA) protein, hepatic ApoAI mRNA and serum reverse cholesterol transport (RCT) markers in the same groups. P-values vs control condition, ANOVA with Dunnett's test.

Figure 8: Isolated hepatic macrophages are sensitive to TLR2 and TLR4-stimulants
(A) Immunofluorescence (F4/80, green, DAPI, blue), showed near complete absence of F4/80⁺ macrophages in liver of mice 3 days after intraperitoneal administration of 1 mg

1 clodronate liposomes (n=8-11/gp). **(B)** Hepatic CD68 mRNA was also significantly reduced
2 by clodronate liposome **(CL)** treatment. **(C)** TNF- α production from liver slices of untreated
3 **(low-fat diet, LFD)**, 4 week **high-fat diet**-primed (HFD), or 4 week HFD primed then CL
4 treated (HFD+CL) mice (n=5/gp) cultured with LPS for 24 h. **(D)** Serum cholesterol levels in
5 mice primed for 4 weeks with HFD, then treated with CL, then orally gavaged with 200 μ l
6 saline alone (Ctrl) or 1 mg LPS, revealed no impact of orally delivered LPS on HDL-C in
7 these mice (n=11/gp). **(E)** Pro-inflammatory cytokine production by **hepatic macrophages**
8 isolated from LFD- or HFD-primed mice treated with medium alone (Ctrl), Pam₃CSK₄ or
9 LPS (n=3-4/gp). **(F)** Flow cytometry for TLR2 and TLR4 expression by RAW macrophages
10 (positive control cell-line), in comparison with **hepatic macrophages** isolated from LFD- or
11 HFD-primed mice (representative of 3 expts). Error bars shown are SEM. **Pairwise**
12 **comparisons by Student's T-test.**

13
14 Figure 9: Interleukin-1 β plays a key role in the downregulation of RCT mediators by
15 hepatocytes in response to products secreted by activated **hepatic macrophages**
16 **(A,B)** Human HepG2 hepatocytes increased **serum amyloid A (SAA)-1**, and reduced ApoAI,
17 mRNA expression significantly in response to IL-1 β , but not stimulants of NOD1 (iEDAP),
18 TLR2 (Pam₃CSK₄) or TLR4 (*E. coli* LPS). **(C)** Conditioned medium of HepG2 cells
19 significantly increased the efflux of ³H-radiolabelled cholesterol from J774 macrophages. **(D)**
20 The capacity of conditioned media of HepG2 hepatocytes to accept ³H-radiolabelled
21 cholesterol effluxed from J774 macrophages was reduced significantly by IL-1 β , but not by
22 IL-6, TNF- α , or stimulants of NOD1, TLR2 or TLR4. **(E)** Flow cytometry showed abundant
23 surface TLR2 and TLR4 on human primary monocytes, but no TLR2 and little TLR4 on
24 HepG2 hepatocytes. Murine primary hepatocytes isolated by hepatic perfusion also showed
25 no expression of TLR2 or TLR4, in **low-fat diet (LFD) or high-fat diet (HFD)**-primed mice
26 (representative of 4 experiments). **(F)** Kinetics of ApoAI protein expression in HepG2 cells
27 treated with IL-1 β determined by Western blot. **(G)** HepG2 ApoAI mRNA response to
28 conditioned medium of LPS-treated human monocytes with isotype-control or IL-1 β
29 neutralising antibody (n=5 expts). **(H,I)** ApoAI and SAA1 mRNA responses of primary
30 hepatocytes (isolated from n=6 LFD-fed mice) to inflammatory cytokines (20 ng/ml). **(J)**
31 ApoAI mRNA responses of primary hepatocytes (n=3 HFD-primed mice) to indicated
32 PAMPs (100 ng/ml). Error bars shown are SEM. **P-values** vs control condition, Student's T-
33 tests or ANOVA with Dunnett's test.

34
35 Figure 10: Interleukin-1 is a key mediator of the lipid and acute phase responses to ingested
36 LPS *in vivo*
37 **(A)** ApoAI mRNA responses of isolated **wild-type (WT)** and **interleukin-1 receptor deficient**
38 **(*Il1r1*^{-/-})** hepatocytes to conditioned medium of LPS-treated WT **hepatic macrophages**. **(B-D)**
39 Plasma **serum amyloid A (SAA)**, lipoprotein cholesterol and hepatic **acute phase response**
40 **(APR)** mRNA responses in HFD-primed *Il1r1*^{-/-} mice 24 h after oral gavage with saline alone
41 (Ctrl) or 1 mg *E. coli* LPS (n=8,10/gp). **(E)** ApoAI protein and efflux capacity in sera of the
42 same mice. **(F)** Hepatic IL-1 β mRNA in LPS-gavaged HFD-primed WT mice treated (or not)
43 with clodronate liposomes (CL). **(G)** IL-1 β mRNA in LPS-treated isolated primary mouse
44 **bone marrow-derived macrophages (BMDM) and hepatic macrophages (HM)**. **(H)** Secreted
45 and **(I)**, cytosolic IL-1 β protein production by LPS and ATP-stimulated primary mouse
46 BMDM and **hepatic macrophage** (n=3-5/gp). **P-values** vs Ctrl, ANOVA with Dunnett's test.

47
48 Figure 11: Suggested model for the accumulation of PAMPs in foods and their impact on
49 APR and RCT mediators

1 The enrichment of the food microbiota in proteobacterial species and their subsequent
2 overgrowth can occur in meat and certain other food products when finely chopped and
3 stored at or above refrigeration temperature. This leads to the accumulation of pro-
4 inflammatory bacterial lipopeptides and lipopolysaccharides, which retain their TLR2 and
5 TLR4-stimulating properties even after cooking has killed remaining viable bacteria (26).
6 These TLR-stimulants may then be absorbed, particularly when intestinal barrier function is
7 impaired, to reach the portal circulation and the liver. Although hepatocytes are insensitive to
8 these stimulants, they may be detected by **hepatic macrophages**, which secrete IL-1 β and
9 other inflammatory cytokines to trigger the APR programme in hepatocytes. This results in
10 reduced serum levels of ApoAI, which is a key mediator of RCT and atherogenesis in mice
11 (55). Modulation of the food microbiota therefore represents a novel potential target for the
12 modulation of systemic inflammatory markers and cholesterol metabolism.

13